Sign in
CompletedPhase 2

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Key facts

Who runs it
Regeneron Pharmaceuticals
Where
Belgium, Bulgaria, Canada, Hungary, Latvia, Lithuania, and Poland16 sites in 7 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
373 people enrolled
Started
24 May 2023
Ended
27 May 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • REGN9933
  • Enoxaparin
  • Apixiban
Record updated
29 August 2025

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Undergoing elective unilateral TKA
  • Has a body weight ≤130 kg at screening visit
  • Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and Electrocardiograms (ECG) performed at screening and/or prior to administration of initial dose of study drug
  • Is in good health based on laboratory safety testing obtained during the screening period as described in the protocol

Who cannot take part

  • History of bleeding in the past 6 months requiring hospitalization or transfusion; history of intracranial or intraocular bleeding, excessive operative or post-operative bleeding, and traumatic spinal or epidural anesthesia; history of bleeding diathesis
  • History of thromboembolic disease or thrombophilia
  • History of major surgery, including brain, spinal, or ocular, within approximately the past 6 months
  • History of major trauma within approximately the past 6 months
  • Using the Modification of Diet in Renal Disease equation, has an estimated glomerular filtration rate as described in the protocol; Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
  • Hospitalized (>24 hours) for any reason within 30 days of the screening visit

This trial has no sites in United States.

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin

Read full original descriptionShow less

The secondary objectives of the study are:

* To evaluate the bleeding risk (ie, major and clinically relevant non-major [CRNM] bleeding) of REGN9933 after unilateral TKA through time of venography, compared to enoxaparin * To assess overall safety and tolerability of REGN9933 in participants undergoing TKA * To evaluate the efficacy of REGN9933 in prevention of clinically relevant VTE, compared to enoxaparin * To evaluate the efficacy of REGN9933 in prevention of deep venous thrombosis (DVT) detected by venography, compared to enoxaparin * To evaluate the pharmacokinetics (PK) of REGN9933 after single intravenous (IV) administration * To assess pharmacodynamic (PD) effects of REGN9933 on intrinsic and extrinsic coagulation pathways * To assess immunogenicity following a single dose of REGN9933 over time * To compare the efficacy of enoxaparin and apixaban in prevention of VTE after unilateral TKA

The 3 groups in the trial

  • REGN9933Treatment being tested

    REGN9933 will be administered by intravenous (IV) infusion

  • EnoxaparinExisting treatment, for comparison

    Enoxaparin will be administered by subcutaneous (SC) administration

  • ApixabanExisting treatment, for comparison

    Apixaban will be administered orally twice a day

    Treatment: Apixiban

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty
Publications
Record updated
29 August 2025